Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2020 Issue has been successfully launched on 1 September 2020.

Abstract

PHARMACOECONOMICS EVALUATION OF TELMISARTAN AS MONOTHERAPY COMPARED WITH TELMISARTAN PLUS HYDROCHLOROTHIAZIDE AS COMBINATION THERAPY IN HYPERTENSIVE PATIENTS

Md Nematullah*, Rizwana Parveen, Rajveer Singh, Ranjeet Kumar

 

ABSTRACT

Background: Hypertension is silent killer it is not a disease it is a disorder. The Pharmacoeconomics study focuses on cost and benefit of the therapy. Monotherapy compared with the combination therapy. Aim: The aim of study to evaluate cost-effectiveness of telmisartan as monotherapy compared with telmisartan plus hydrochlorothiazide as combination therapy in hypertensive patients in tertiary care teaching hospital, Jaipur. Methods: A prospective observational study of six month conducted on the hypertension patients at general male medicine ward and female medicine ward with n=80 patients. A systemic protocol followed to obtained permission Institutional Ethical Committee (IEC) by submitting a proper protocol, data collection form, patient information and patient consent form. Result: Out of 80 patients it was found that in the study the cost of telmisartan was less and more cost-effectiveness as compare to telmisartan plus HCTZ. Conclusion: Telmisartan is a cost-saving therapy compared with Telmisartan plus HCTZ in HTN patients.

Keywords: Telmisartan, Telmisartan plus hydrochlorothiazide, Hypertension.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More